KURLAND FRED 4/A
4/A · Aridis Pharmaceuticals, Inc. · Filed Aug 29, 2019
Insider Transaction Report
Form 4/AAmended
KURLAND FRED
Chief Financial Officer
Transactions
- Award
Stock Options
2018-12-05+17,000→ 39,575 totalExercise: $8.50Exp: 2028-12-05→ Common Stock (17,000 underlying)
Footnotes (2)
- [F1]The shares underlying this stock option vest in equal installments over the 48 months following the date of grant. The original Form 4 stated that vesting occurred in equal annual installments over the same period.
- [F2]Due to a clerical error, the reporting person is filing this Amendment to correct the amount of derivative securities beneficially owned following the reported transaction from 39,574 to 39,575.